Zacks Investment Research upgraded shares of Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) from a sell rating to a hold rating in a research note published on Friday morning, Zacks.com reports. According to Zacks, “Neurocrine Biosciences is a neuroscience-based company focused on the discovery and development of novel therapeutics for neuropsychiatric, neuroinflammatory and neurodegenerative diseases and […]
Russell Investments Group Ltd. boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 48.6% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,871 shares of the company’s stock after acquiring an additional 16,648 shares during the quarter. […]
/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 2022 CNS Days virtual conference at 3:30 p.m. Eastern Time on Monday,.
State of Alaska Department of Revenue decreased its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 5.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 13,731 shares of the company’s stock after selling 795 shares during the period. State of Alaska Department of Revenue’s holdings in Neurocrine Biosciences were worth $1,169,000 […]
/PRNewswire/ Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that members of the management team will participate at the following investor.